Optimization of the conditions for preservation of induced sputum: influence of freezing on cellular analysis

HOPE-preservation of paraffin-embedded sputum samples--a new way of bioprofiling in COPD

Induced sputum is a non-invasive sampling technique for the analysis of airway inflammation in various lung diseases and comprises valuable potential for the identification of biomarkers and therapeutic targets by molecular methods. In the context of biobanking with preservation of induced sputum samples for subsequent analyses we applied the HEPES-glutamic acid buffer-mediated organic solvent protection effect (HOPE)-technique for preparation of induced sputum samples. Induced sputum samples of 20 patients with moderate to severe chronic obstructive pulmonary disease (COPD) and 12 healthy controls were collected. Cell pellets of induced sputum samples were preserved with HOPE and subsequently embedded in paraffin. Immunostaining of paraffin-block sections for interleukin-8, interleukin-17, myeloperoxidase, matrixmetalloproteinase-9, CD68, and CD8 revealed distinct signals without antigen retrieval. Moreover, RNA was extracted and successfully used for transcription microarray analysis. Sputum samples preserved by the HOPE-technique display a tool to address scientific approaches in pulmonary research, which can enable the identification of new biomarkers and therapeutic targets in respiratory diseases.

Circadian changes in the sputum of asthmatic subjects and healthy controls

Background

Asthma is exhibiting classical circadian fluctuations of clinical symptoms and airflow measurements, presumably influenced by the underlying airway inflammation and the endogenous cortisol secretion. The aim of our study was to examine the cellular and eosinophilic cationic protein (ECP) contents of sputum, collected and frozen at 2 opposite time points of the day-and-night cycle, and to correlate them to blood cortisol levels.

Methods

Thirteen subjects with uncontrolled asthma (8 men, aged 25-54 years) and 10 healthy subjects (6 men, aged 25-50 years) volunteered for the study. They were induced with hypertonic saline to produce sputum between 8:00 AM and 9:00 AM and between 8:00 PM and 9:00 PM, when blood was also withdrawn to measure cortisol levels.

Results

Asthmatic subjects did not display significant morning/evening differences in their sputum total cell counts ([TCCs] median, 2.06 × 10³ cells/mL; range 0.50-5.66 cells/mL vs median, 1.29 cells/mL; range, 0.24-9.26 cells/mL, P > 0.1), whereas controls had a well-defined morning peak (median, 0.75 cells/mL; range, 0.31-2.25 cells/mL vs median, 0.33 cells/mL; range, 0.1-0.97 cells/mL, P > 0.001). Asthmatic subjects had significantly higher sputum TCC than controls in the evening (P < 0.001), but their morning TCC did not significantly exceed those of the healthy subjects. Asthmatic subjects had significantly more sputum eosinophils and higher ECP levels than controls but failed to demonstrate significant morning/evening differences in contrast to the controls who had higher morning eosinophils and ECP. Macrophages were relatively increased in the evening samples of both asthmatic subjects and controls. No significant correlations between the circadian cortisol shift and any of the sputum indices were found.

Conclusions

Sputum undergoes circadian changes, which are different in health and in asthma and do not correlate with endogenous cortisol levels.

[Time trends of Th1 and th2 cytokines in induced sputum of asthmatic subjects during acute upper respiratory viral infections]

Fundamento

Muchas de las exacerbaciones del asma se deben a infecciones víricas de las vías respiratorias que inducen una interacción de respuestas inmunitarias entre Th1 y Th2. Sin embargo, las tendencias temporales de estas respuestas durante estos fenómenos no se han estudiado con detalle.

Objetivo

Identificar los posibles mecanismos subyacentes de la relación entre las infecciones víricas respiratorias y las exacerbaciones del asma.

Pacientes y métodos

Seleccionamos 40 adultos, de 21–58 años de edad, en 4 grupos: A, sanos; B, sanos con infección vírica; C, con asma leve o moderada, y D, igual que C pero con infección vírica. Durante el curso de una infección vírica aguda de las vías respiratorias superiores se monitorizaron las citocinas Th1 y Th2 en muestras de esputo inducido en individuos por lo demás sanos y en pacientes asmáticos. La interleucina (IL) 4, la IL-5 y el interferón gamma (IFN-γ) se analizaron mediante un método ELISA. Se monitorizaron las puntuaciones de los síntomas de infección vírica y de gravedad del asma. Las tendencias temporales se analizaron mediante la utilización de modelos mixtos lineales.

Resultados

En los grupos C y D los valores de IL-4 e IL-5 fueron mayores que en los grupos A y B. En el grupo B, los valores de IFN-γ y las puntuaciones de síntomas de infección vírica fueron máximos en el día 2 y disminuyeron rápidamente en el día 7, mientras que en el grupo D los valores de IFN-γ y las puntuaciones de síntomas de infección vírica y de asma alcanzaron un máximo mucho más tarde (días 3–5) y disminuyeron lentamente. En el grupo D, los cocientes IL-4 e IL-5:IFN-γ fueron significativamente más altos que en el grupo C.

Conclusiones

Las exacerbaciones del asma inducidas por las infecciones pueden deberse a un deterioro de las respuestas inmunitarias antivíricas Th1. Parece identificarse un intervalo decisivo de 3–5 días para instaurar una intervención terapéutica.

Down-titration from high-dose combination therapy in asthma: Removal of long-acting beta(2)-agonist

BACKGROUND

Asthma guidelines recommend reducing inhaled corticosteroids (ICS) to the minimum effective dose, but the timing of long-acting beta(2)-agonist (LABA) withdrawal is unclear. Recent FDA guidelines recommend LABA withdrawal once asthma is well-controlled. This 13-month double-blind study of patients taking high-dose combination therapy investigated the effect of discontinuation of LABA before ICS down-titration.

METHODS

Adults using salmeterol/fluticasone combination (SFC) 50/500 microg bd were randomized to SFC 50/500 microg bd or fluticasone propionate (FP) 500 microg bd, with subsequent ICS down-titration 8-weekly using a clinical algorithm. The primary outcome was mean daily FP dose, including ICS for exacerbations.

RESULTS

82 subjects were randomized. Asthma was well-controlled at baseline, with mean FEV(1) 84.8% predicted and Asthma Control Questionnaire (ACQ) score 0.9. There was no significant difference in mean daily FP dose (SFC: 721 microg, FP:816 microg, p = 0.3), but final dose was lower with SFC (534 microg cf. 724 microg, p = 0.005). ICS dose was reduced by >or=80% in 41% SFC and 15% FP patients. Ambulatory lung function was significantly higher with SFC, but there were no differences between groups in rescue beta(2)-agonist use, clinic spirometry, airway responsiveness, ACQ, sputum eosinophils or FeNO. Baseline airway responsiveness, and pre-reduction blood eosinophils, were significant predictors of mean daily FP dose and dose reduction failure respectively.

CONCLUSIONS

Many patients prescribed high-dose combination therapy may be over-treated. Substantial reductions in dose can be achieved with a clinical algorithm, reaching lower FP doses with SFC than FP without losing asthma control or increasing disease activity.

TRIAL REGISTRATION

This study was commenced before mandatory registration of clinical trials.

Alveolar macrophage subpopulations in bronchoalveolar lavage and induced sputum of asthmatic and control subjects

BACKGROUND

Alveolar macrophages (AM) are the most numerous immune cells in the airways and are involved in the immunological homeostasis of the lung. Intriguingly, their role in asthma remains unclear probably, in part, because of their heterogeneity.

OBJECTIVE

To characterize AM population from bronchoalveolar lavage (BAL) and induced sputum (IS) of asthmatic and normal subjects using specific biomarkers.

METHODS

Non-asthmatic non-allergic and allergic mild asthmatic subjects were recruited for this study. AM were obtained from BAL and IS and cytospins were prepared. Immunocytochemistry was performed for nine cellular markers (CD68, RFD7, CD14, CD11b, CD83, CD64, CD80, CD86, and FIZZ1).

RESULTS

Asthmatic subjects had more AM RFD7(+) in BAL compared with IS, whereas control subjects had more AM RFD7(+) in IS than in BAL. Consequently, there was an increased number of AM RFD7(+) in BAL of asthmatic subjects compared with BAL of control subjects. AM CD11b(+) was higher in BAL than in IS in both groups. The expression of FIZZ1, marker of macrophage alternative activation, was similar in asthmatic and normal subjects.

CONCLUSION

The expression of cellular markers on AM differs according to their localization in the lung. Subpopulations of AM may contribute to the inflammatory profile observed in asthmatic subjects.

Loss of detectability of Charcot-Leyden crystal protein transcripts in blood cells after treatment with dimethyl sulfoxide

Charcot-Leyden crystal protein (CLC) is a major secretory effector protein of eosinophils. In addition, CLC has been identified as marker for regulatory T-cells and differential expression of CLC has been described under diverse pathological conditions. By analysis of DNA microarray data from peripheral blood mononuclear cells (PBMC) we found differences for the expression of CLC between PBMC that had been cryopreserved or had been used for RNA isolation immediately after cell separation. Reverse transcriptase-polymerase chain reaction (RT-PCR) of separated cell populations indicated that contaminating granulocytes were the main source of CLC transcripts in PBMC. CLC was only detectable in fresh PBMC and not in cryopreserved material. Transcripts corresponding to CLC were also detectable by RT-PCR only in fresh PBMC and eosinophils. Loss of CLC transcripts in PBMC was induced by a short pulse with dimethyl sulfoxide (DMSO), indicating that the freezing medium was responsible for this phenomenon. We conclude that CLC transcripts are lost during cryopreservation in the presence of DMSO and can never be identified as differentially expressed in cryopreserved samples.